Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water and sodium excretion. Inhibition of V2R increases vasopressin concentration in plasma, which stimulates V1-receptors in the vascular bed and may change both central and brachial hemodynamics and plasma concentration of vasoactive hormones. The purpose of the study is to measure the effects of tolvaptan on renal handling of water and sodium, systemic hemodynamics and vasoactive hormones at baseline and during nitric oxide (NO)-inhibition with L-NG-monomethyl-arginine (L-NMMA).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
15
15 mg pr day for 1 day
30 mg pr day for 1 day
45 mg pr day for 1 day
Department of medical research
Holstebro, Denmark
CH2O
Measurement of H2O clearance at baseline, during and after L-NMMA infusion
Time frame: 5-6 Hours
Urine biomarkers(Aquaporins and Epithelial Sodium Channels γ)
Time frame: 5-6 Hours
Central and brachial blood pressure
Time frame: 5-6 Hours
Augmentation Index
Time frame: 5-6 Hours
Vasoactive Hormones( Angiotensin II, Aldosterone, Endothelin, Atrial Natriuretic Peptide, Brain Natriuretic Peptide, Arginin Vasopressin)
Time frame: 5-6 Hours
Fractional sodium excretion
Measurement of Sodium excretion at baseline, during and after L-NMMA infusion.
Time frame: 5-6 Hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
1 tablet Unikalk pr day for 1 day